enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 72,700 shares, an increase of 472.4% from the March 31st total of 12,700 shares. Based on an average daily volume of 51,000 shares, the short-interest ratio is presently 1.4 days. Approximately 1.0% of the shares of the company are sold short.

Analysts Set New Price Targets

ENGN has been the topic of several analyst reports. UBS Group assumed coverage on enGene in a research report on Thursday, March 28th. They issued a “buy” rating and a $37.00 target price on the stock. Guggenheim assumed coverage on shares of enGene in a report on Monday, April 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Wells Fargo & Company began coverage on shares of enGene in a research note on Monday. They set an “overweight” rating and a $30.00 target price for the company. Morgan Stanley began coverage on shares of enGene in a research report on Friday, March 8th. They issued an “overweight” rating and a $40.00 target price for the company. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $34.40.

enGene Stock Down 0.2 %

ENGN stock traded down $0.03 during trading on Thursday, hitting $14.72. The company had a trading volume of 48,417 shares, compared to its average volume of 43,550. The firm has a 50 day moving average price of $16.21. enGene has a fifty-two week low of $6.69 and a fifty-two week high of $43.00.

Insider Buying and Selling at enGene

In related news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now owns 3,036,153 shares in the company, valued at $45,542,295. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Trading of enGene

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Fcpm Iii Services B.V. acquired a new position in shares of enGene during the fourth quarter valued at approximately $80,097,000. BVF Inc. IL acquired a new stake in enGene in the fourth quarter worth approximately $20,777,000. Omega Fund Management LLC bought a new position in enGene during the 4th quarter valued at $10,441,000. Finally, Vivo Capital LLC acquired a new position in shares of enGene during the 4th quarter valued at $6,264,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.